Abstract 2150
Background
A decrease in AFP level during treatment has been associated with improved overall survival (OS) in patients with HCC. In the phase 3 RESORCE trial (NCT01774344), the multikinase inhibitor regorafenib significantly improved OS versus placebo in patients with HCC and disease progression on sorafenib. We analyzed OS in patients who had an AFP response in RESORCE.
Methods
Patients with Barcelona Clinic Liver Cancer stage B or C HCC, Child -Pugh A liver function, ECOG performance status 0 − 1, and documented radiologic progression on prior sorafenib were randomized 2:1 to regorafenib 160 mg/day (n = 379) or placebo (n = 194) for Weeks 1-3 of each 4-week cycle. Serum AFP levels were assessed at baseline, every 4 weeks during treatment, and at the end of treatment. Patients who had a baseline AFP ≥20 ng/mL and an AFP measurement at the start of Cycle 3 were evaluable for AFP response, defined as a decrease of ≥ 20% in AFP level from baseline at the start of Cycle 3.
Results
Overall, 232 of the 573 randomized patients fulfilled the above criteria and were included in the analysis. Patients with an AFP response had a median OS from randomization of 13.8 months vs 8.9 months in those without an AFP response (Table). The rate of AFP response was 46% (77/168) in the regorafenib group and 11% (7/64) in the placebo group. Among regorafenib-treated patients, the median OS was 13.8 months in patients with an AFP response vs 9.8 months in those without an AFP response. A landmark analysis of OS from the start of Cycle 3 showed that the hazard ratios for AFP response vs no response were 0.57 (95% CI 0.40, 0.82) in the regorafenib and placebo arms combined and 0.72 (95% CI 0.48, 1.08) for patients in the regorafenib arm.Table:
755P
Regorafenib + /placebo arms combined | Regorafenib arm | |||
---|---|---|---|---|
(n = 232) | (n = 168) | |||
AFP response (n = 84) | No AFP response (n = 148) | AFP response (n = 77) | No AFP response (n = 91) | |
Median OS (95% CI) from randomization, months | 13.8 (11.8, 16.5) | 8.9 (8.0, 9.7) | 13.8 (11.7, 16.5) | 9.8 (8.2, 14.2) |
HR (95% CI) AFP response yes/no | 0.57 (0.40, 0.82) | 0.72 (0.48, 1.07) | ||
CI, confidence interval; HR, hazard ratio. |
Conclusions
In this exploratory analysis of RESORCE, an AFP response with regorafenib was associated with improved OS.
Clinical trial identification
NCT01774344.
Editorial acknowledgement
Jennifer Tobin of OPEN Health Medical Communications (London, UK), with financial support from Bayer.
Legal entity responsible for the study
Bayer.
Funding
Bayer.
Disclosure
J. Bruix: Honoraria (self): Bayer; BTG; Eisai; Ipsen; Sirtex; Terumo; Advisory / Consultancy: AbbVie; Adaptimmune; Arqule; Astra-Medimmune; Basilea; Bayer; Bio-Alliance; Bristol-Myers Squibb; BTG; Eisai; Gilead; Incyte; Ipsen; Kowa; Lilly; Merck Sharp & Dohme; Nerviano; Novartis; Quirem; Roche; Sanofi Aventis; Sirtex; Terumo; Research grant / Funding (institution): Bayer; BTG. M. Reig: Honoraria (self): AstraZeneca; Bayer; Bristol-Myers Squibb; BTG; Gilead; Ipsen; Lilly; Advisory / Consultancy: AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Lilly; Roche; Research grant / Funding (institution): Bayer; Travel / Accommodation / Expenses: Bayer; Bristol-Myers Squibb; Gilead; Ipsen; Lilly. P. Merle: Advisory / Consultancy: AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Merck Sharp & Dohme; Onxeo; Roche. M. Kudo: Honoraria (self): Bayer; Eisai; Merck Sharp & Dohme; Advisory / Consultancy: Bayer; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Research grant / Funding (institution): AbbVie; Astellas Pharma; Bristol-Myers Squibb; Chugai; Daiichi Sankyo; EA Pharma; Eisai; Gilead; Medico’s Hirata; Otsuka; Taiho; Takeda. G. Meinhardt: Shareholder / Stockholder / Stock options: Bayer; Full / Part-time employment: Bayer. M. Zhang: Shareholder / Stockholder / Stock options: Bayer; Full / Part-time employment: Bayer. K. Ozgurdal: Full / Part-time employment: Bayer.
Resources from the same session
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
2145 - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Presenter: Takahiro Yokose
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract
3951 - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms
Presenter: Sofia Ferreira
Session: Poster Display session 2
Resources:
Abstract